Abstract 901P
Background
Chemoradiation (CRT) in patients (pts) with locally advanced head and neck squamous cell cancer (HNSCC) is associated with significant toxicities, including oral mucositis (OM). The gut microbiome (GM) is an emerging biomarker of treatment outcomes and adverse events. This study aimed to investigate the role of GM composition to predict CRT toxicities in HNSCC pts, including development of severe OM.
Methods
We prospectively collected fecal samples of 52 pts with HNSCC undergoing CRT. Using shotgun metagenomic sequencing and MetaPhlAn4 pipeline, LefSe differences in GM composition at baseline were assessed according to CTCAE v4.0 toxicity grading including OM and enteral feeding tube requirement. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method.
Results
Most tumors (n=40) were p16-positive, including oropharyngeal (n=35) and unknown primaries (n=4). TNM staging was III-IV in 54% (n=28). After a median follow-up of 27 mo, the 12-mo OS and PFS were 96% and 84%, respectively. In terms of toxicity, OM was seen in all pts, and 22 pts (42%) developed grade ≥3 OM. Thirteen pts (25%) required enteral feeding. Grade ≥3 OM was associated with a significant decrease in OS (p=0.02) even when accounting for staging and p16 status in multivariate analysis (MVA; p<0.05), as well as a numerically shorter PFS (p=0.09). No baseline characteristic correlated with increased risk of severe OM in MVA. However, GM beta-diversity differed between grade 1-2 and grade 3 OM (PERMANOVA p=0.04) but there was no difference in alpha-diversity. Pts with severe OM had distinct GM enriched with Mediterraneibacter (Ruminococcus gnavus) and members of the Clostridiaceae family, including Hungatella hathewayi. In pts with mild OM, Eubacterium rectale, Alistipes putredinis and members of the Ruminococcaceae family were overrepresented. We observed similar microbiome differences in pts requiring enteral feeding.
Conclusions
Severe OM was associated with decreased OS and PFS in pts with HNSCC undergoing CRT. Pts who developed severe OM or required enteral feeding had a distinct GM enriched with deleterious bacteria that have been associated with resistance to immune checkpoint inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Oncobiome grant #825410.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
922P - Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
Presenter: Glenn Hanna
Session: Poster session 12
923P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Presenter: Christophe Le Tourneau
Session: Poster session 12
924P - Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)
Presenter: Kevin Harrington
Session: Poster session 12
925P - Treatment discontinuation of immune checkpoint blockade in patients with head and neck squamous cell carcinoma experiencing complete or nearly complete remission
Presenter: Konrad Klinghammer
Session: Poster session 12
926P - UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
927P - Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
Presenter: Boris Kubuschok
Session: Poster session 12
928P - Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
Presenter: Zara Vidales Sepulveda
Session: Poster session 12
930P - Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer (HNSCC)
Presenter: Marcelo Bonomi
Session: Poster session 12
931P - Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Presenter: Pasvich Pitakpaiboonkul
Session: Poster session 12